TA1 vs Zinc Injection
A side-by-side research comparison of TA1 and Zinc Injection across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | Zinc Injection |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Zinc Sulfate Injectable |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Compounded supplement |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | Essential cofactor for 300+ enzymes. Critical for T-cell maturation, NK cell activity, zinc finger protein transcription factors, testosterone synthesis, and wound healing metalloproteinases. |
| Molecular weight | 3108.3 Da | 287.56 Da |
| Half-life | ~2-3 hours | Stored in tissues (~2-3 week turnover) |
| Bioavailability | ~85% subcutaneous | ~100% injectable |
| Typical dose | 1.6 mg | 5-10 mg elemental zinc |
| Frequency | 2x per week | 1-2x per week |
| Route | Subcutaneous injection | Intramuscular or IV injection |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Zinc Injection reported benefits
- Immune system support
- Testosterone production
- Wound healing
- Thyroid function
- Antioxidant support
Related comparisons
Research and educational reference only. Not medical advice.